In Brief: Generic bioequivalence
Generic bioequivalence: FDA sent a second letter defending its bioequivalence determinations to physician organizations and state boards of pharmacy on Jan. 28. Associate Commissioner for Health Affairs Stuart Nightingale, MD, concluded that "products evaluated as therapeutically equivalent can be expected to have equivalent clinical effect whether the product is brand name or generic." A similar letter was sent in April by Deputy Center Director for Pharmaceutical Science Roger Williams, MD ("The Pink Sheet" April 28, p. 5)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth